NCT03618420View on ClinicalTrials.gov

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

October 19, 2019

Study Completion Date

August 1, 2021

Conditions
Diabetes Mellitus, Type 1NephropathyDiabetic NephropathiesJuvenile DiabetesDiabetes Mellitus ComplicationAutoimmune DiabetesType 1 Diabetes Mellitus
Interventions
DRUG

Aminohippurate Sodium Inj 20%

Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

DRUG

Iohexol Inj 300 mg/mL

Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function | Biotech Hunter | Biotech Hunter